Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

1279804

USP

Fluoxétine hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(±)-N-Méthyl-γ-[4-(trifluorométhyl)phénoxy]benzènepropanamine hydrochloride, LY-110,140 hydrochloride, Prozac®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H18F3NO · HCl
Numéro CAS:
56296-78-7
Poids moléculaire :
345.79
Numéro MDL:
MFCD00214288
Code UNSPSC :
41116107
ID de substance PubChem :
329749876
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluoxetine

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CNCCC(C1=CC=CC=C1)OC2=CC=C(C(F)(F)F)C=C2.[H]Cl

InChI

1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H

Clé InChI

GIYXAJPCNFJEHY-UHFFFAOYSA-N

Informations sur le gène

human ... SLC6A4(6532)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Fluoxetine hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluoxetine Tablets
  • Fluoxetine Delayed-Release Capsules
  • Olanzapine and Fluoxetine Capsules
  • Fluoxetine Oral Solution
  • Fluoxetine Capsules

Actions biochimiques/physiologiques

Inhibiteur sélectif de la recapture de la sérotonine ; antidépresseur.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Informations légales

Vendu sous licence de Eli Lilly and Co.
Prozac is a registered trademark of Eli Lilly and Co.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

F0253030

Fluoxetine impurity C, European Pharmacopoeia (EP) Reference Standard

1279826

Fluoxetine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1279837

Fluoxetine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1279815

Fluoxetine Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP797

Fluoxétine hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR1953

Fluoxetine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1952

Fluoxetine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2041

Fluoxetine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002201

Fluoxetine impurity A, CRS, European Pharmacopoeia (EP) Reference Standard

Y0002219

Fluoxétine hydrochloride, CRS, European Pharmacopoeia (EP) Reference Standard

Mention d'avertissement

Danger

Mentions de danger

H302,H318,H336,H373,H410

Classification des risques

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - STOT RE 2 - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

R J Gonzalez-Rothi et al.
Chest, 107(6), 1763-1765 (1995-06-01)
We describe a patient who developed progressive dyspnea, lung infiltrates, and restrictive lung disease in association with the antidepressant fluoxetine hydrochloride (Prozac). The pathologic findings were consistent with hypersensitivity pneumonitis. An associated pulmonary phospholipidosis was also noted.
Paulina Jedynak et al.
Journal of psychiatric research, 56, 106-111 (2014-06-17)
The neurogenesis hypothesis of major depression has two main facets. One states that the illness results from decreased neurogenesis while the other claims that the very functioning of antidepressants depends on increased neurogenesis. In order to verify the latter, we
Sean C Godar et al.
Journal of psychiatric research, 56, 1-9 (2014-06-03)
The termination of serotonin (5-hydroxytryptamine, 5-HT) neurotransmission is regulated by its uptake by the 5-HT transporter (5-HTT), as well as its degradation by monoamine oxidase (MAO)-A. MAO-A deficiency results in a wide set of behavioral alterations, including perseverative behaviors and
Kristie T Ota et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(3), 711-718 (2014-09-03)
Major depressive disorder (MDD) is a debilitating and widespread illness that exerts significant personal and socioeconomic consequences. Recent genetic and brain-imaging studies suggest that bicaudal C homolog 1 gene (BICC1), which codes for an RNA-binding protein, may be associated with
Rody Kingston et al.
PLoS genetics, 17(11), e1009885-e1009885 (2021-11-05)
Molecular insights into the selective vulnerability of retinal ganglion cells (RGCs) in optic neuropathies and after ocular trauma can lead to the development of novel therapeutic strategies aimed at preserving RGCs. However, little is known about what molecular contexts determine
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique